InvestorsHub Logo
Followers 1
Posts 131
Boards Moderated 0
Alias Born 09/12/2017

Re: Ryoko post# 5290

Monday, 05/20/2019 11:25:05 AM

Monday, May 20, 2019 11:25:05 AM

Post# of 6939
Today's meeting is about manufacturing, the June 6 meeting is about the BLA submission. From a Friday afternoon SA article:

"A Type C CMC meeting is scheduled for May 20 to discuss the best path for the transfer of technology to Fujifilm to ensure that product quality and integrity are maintained. Per the press release, the recently completed full-scale GMP manufacturing run at Fujifilm’s facility yielded “encouraging preliminary results”. The June 6 pre-BLA meeting’s primary objective is to obtain feedback from the agency as to whether the efficacy and safety data, benefit-risk profile and overall information that has been compiled is adequate for BLA submission. Among oncology products reviewed by the FDA between 2006 and 2015, the approval rate for those that get through BLA filing is 82%, significantly higher than the 33% that get through Phase 3. (bold highlight is mine)

Link to full article:
https://seekingalpha.com/article/4264984-sesen-bio-looks-better-ever-update

Looking very positive based on reward / risk of Vicinium.